LIAN News and Press, LianBio From 04/26/23

2023-04-26 08:53:02 ET Bristol Myers Squibb ( NYSE: BMY ) and LianBio's ( NASDAQ: LIAN ) drug Camzyos (mavacamten) met the main goal of a phase 3 trial in Chinese patients with a type of heart disease. LianBio was evaluating mavacamten in the study, dubbed EXPLORE...

• Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a safety profile consistent with previous studies • If approved, mavacamten is expected t...

2023-04-21 09:09:00 ET China's National Medical Products Administration (NMPA) granted priority review to Bristol Myers Squibb ( NYSE: BMY ) and  LianBio's ( NASDAQ: LIAN ) drug Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyop...

2023-04-21 08:39:48 ET LianBio ( NASDAQ: LIAN ) has announced the promotion of Pascal Qian to the position of Chief Commercial Officer and he will continue to also serve as the Co.’s China General Manager. In his expanded role as Chief Commercial Officer, he will le...

SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the promotion of Pascal Qian to the position of Chief Commercial O...

SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that China’s National Medical Products Administration (NMPA...

2023-03-27 09:30:36 ET LianBio press release ( NASDAQ: LIAN ): Q4 GAAP EPS of -$0.17. Cash, cash equivalents and marketable securities at December 31, 2022 totaled $302.4 million, For further details see: LianBio GAAP EPS of -$0.17

Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing, with data expected mid-year 2023 Phase 3 registrational trial of TP-03 in Chinese patients with Demodex blepharitis ongoing, with data expected in the fourth quarter ...

Summary Sichuan Kelun-Biotech will partner seven preclinical antibody-drug conjugate assets with Merck in a deal that pays Kelun-Biotech $175 million upfront and up to $9.3 billion in milestones - the third ADC deal between the two companies this year. LianBio announced that Pfizer will...

Pfizer will now lead all development and commercialization activities in Mainland China, Hong Kong, Macau, and Singapore LianBio will receive a $20 million upfront payment, to be released from previously restricted cash paid by Pfizer to LianBio in 2020 under the companies’ existin...